KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2025)

Alnylam Pharmaceuticals' Work In Process history spans 8 years, with the latest figure at $65.1 million for Q4 2025.

  • For Q4 2025, Work In Process changed 0.22% year-over-year to $65.1 million; the TTM value through Dec 2025 reached $65.1 million, changed 0.22%, while the annual FY2025 figure was $65.1 million, 0.22% changed from the prior year.
  • Work In Process reached $65.1 million in Q4 2025 per ALNY's latest filing, up from $35.5 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $116.7 million in Q2 2023 to a low of $23.6 million in Q1 2021.
  • Average Work In Process over 5 years is $73.0 million, with a median of $73.0 million recorded in 2024.
  • Peak YoY movement for Work In Process: soared 525.07% in 2021, then tumbled 49.18% in 2025.
  • A 5-year view of Work In Process shows it stood at $100.9 million in 2021, then grew by 12.72% to $113.8 million in 2022, then crashed by 32.36% to $77.0 million in 2023, then fell by 15.57% to $65.0 million in 2024, then rose by 0.22% to $65.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Work In Process are $65.1 million (Q4 2025), $35.5 million (Q3 2025), and $43.8 million (Q2 2025).